Clomixyl 50 mg

Clomixyl 50 mg contains clomiphene citrate, which is FDA-approved for the treatment of ovulatory dysfunction in women desiring pregnancy. In non-medical bodybuilding contexts, clomiphene is commonly referenced in PCT protocols after anabolic steroid cycles to help restore endogenous testosterone production, though such use falls outside approved indications.

In FDA-approved medical use for women, clomiphene citrate is typically dosed at 50 mg daily for 5 days, starting on or about the 5th day of the cycle. In clinical research in male bodybuilders for PCT, clomiphene has been studied at 25 mg/day as monotherapy. Non-medical PCT protocols commonly reference 50/50/25/25 mg over 4 weeks.

Clomiphene is itself commonly used as a PCT agent. It does not suppress the HPG axis and is used to stimulate endogenous testosterone production after suppressive anabolic steroid cycles. Standard non-medical PCT protocols reference clomiphene at 50/50/25/25 mg over 4 weeks. The efficacy of PCT is still unproven, and medical guidance is advised.

Clomiphene citrate blocks estrogen receptors in the hypothalamus, reducing the negative feedback normally exerted by circulating estrogens on the HPG axis. This stimulates GnRH release, which promotes LH and FSH secretion from the anterior pituitary. The increase in LH enhances testosterone production in the Leydig cells, while FSH supports spermatogenesis.

Clomiphene stimulates gonadotropin release relatively quickly, but effects on testosterone levels and recovery of the HPG axis may take weeks to manifest. In a 2026 study in recreational bodybuilders, clomiphene citrate monotherapy (25 mg/day) facilitated earlier hormonal normalization compared to no treatment.

There is no single PCT agent that is universally best. Clomiphene is commonly referenced in PCT protocols, as is Nolvaxyl 20 mg (tamoxifen). A 2026 study found that adding hCG to clomiphene was associated with superior recovery of semen parameters and testicular volume compared to clomiphene alone. The appropriate approach depends on individual factors and medical guidance.

Both clomiphene and tamoxifen are selective estrogen receptor modulators (SERMs) commonly referenced in PCT protocols. Clomiphene blocks estrogen receptors in the hypothalamus to stimulate gonadotropin release. Tamoxifen is also used for this purpose. The choice between them depends on individual response and medical guidance.

Clomiphene is a SERM that blocks estrogen receptors, while anastrozole is an aromatase inhibitor that reduces estrogen production by blocking the aromatase enzyme. Clomiphene is commonly referenced for PCT, while anastrozole is sometimes referenced for managing estrogenic side effects during cycles. Anastrozole is available as Arimixyl 1 mg.

A 50 mg tablet represents the standard FDA-approved daily dose for women with ovulatory dysfunction. In clinical research in male bodybuilders for PCT, clomiphene has been studied at 25 mg/day. Non-medical PCT protocols commonly reference starting at 50 mg and tapering down.

Clomixyl 50 mg is labeled at 50 mg of clomiphene citrate per tablet. It is supplied in packs of 30 or 100 tablets.

Clomiphene citrate stimulates FSH release, which supports spermatogenesis through its effect on Sertoli cells. A 2026 study in recreational bodybuilders found that adding hCG to clomiphene was associated with superior recovery of semen parameters compared to clomiphene alone. However, the FDA notes there are no adequate studies demonstrating effectiveness in male infertility.

Laboratory testing information for Clomixyl 50 mg is not currently available in this product listing. Kalpa Pharmaceuticals products are manufactured under pharmaceutical-grade conditions, but independent lab reports are not published for this specific product at this time.